Mycophenolate mofetil: Effects on clinical transplantation

BioDrugs

Volumn 10, Issue 5, 1998, Pages 373-384

  Holt, Curtis D ^a,d   Sievers, Theodore M ^b   Ghobrial, Rafik M ^a   Rossi, Steven J ^c   Goss, John A ^a   McDiarmid, Sue V ^a  

^a UCLA MEDICAL CENTER   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c Sangstat Medical   (United States)

^d Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PLACEBO; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

B LYMPHOCYTE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; GASTROINTESTINAL TOXICITY; GRAFT REJECTION; GROWTH INHIBITION; HEART TRANSPLANTATION; HEMATOLOGIC DISEASE; HUMAN; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 0031729484     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199810050-00004     Document Type: Review

References (58)

1. Lindholm A, Ohlman S, Albrechtsen D, et al. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation 1993; 56: 307-15
2. Koyama H, Cecka JM. Rejection episodes. In: Terasaki P, Cecka JM, editors. Clinical transplants 1992. Los Angeles: UCLA Tissue Typing Laboratory, 1992: 391-404
3. Nelson P, Eugui E, Allison AC. Synthesis and immunosuppressive activity of some side-chain variants of mycophenolic acid. J Med Chem 1990; 33: 833-8
4. Lee W, Gu L, Miksztal AR, et al. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 1990; 7: 161-6
5. Sollinger HW, Deierhoi MH, Belzer FO, et al. RS-61443- a phase I clinical trial and pilot rescue study. Transplantation 1992; 53: 428-32
6. Sollinger HW, Belzer FO, Deierhoi MH, et al. RS-61443 (mycophenolate mofetil): a multicenter study for refractory kidney transplant rejection. Ann Surg 1992; 216: 513-9
7. Ensley RD, Bristow MR, Olsen SL, et al. The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation 1993; 56: 75-82
8. Klintmalm GB, Ascher NL, Busuttil RW, et al. RS-61443 for treatment-resistant liver rejection. Transplant Proc 1993; 25: 697
9. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-32
10. European Mycophenolate mofetil study group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroid for prevention of acute rejection. Lancet 1995; 345: 1321-5
11. The Tricontinental mycophenolate mofetil renal transplantation study group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-37
12. The mycophenolate mofetil renal refractory rejection study group. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. Transplantation 1996; 61: 722-9
13. Penn I. The changing pattern of posttransplant malignancies. Transplant Proc 1991; 23: 1101-3
14. Hanto DW, Frizzera G, Purtilo DT, et al. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res 1981; 41: 4253-61
15. Eugui EM, Almquist SJ, Muller CD, et al. Lymphocyte selective cytostatic and immunosuppressive effects of mycophenolate acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991; 33: 161-73
16. Gregory CR, Pratt RE, Huie P, et al. Effects of treatment with cyclosporine, FK506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular smooth muscle proliferation in vitro and in vivo. Transplant Proc 1993; 25: 770-1
17. Morris RE, Wang J, Blum JR, et al. Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and non-human primate recipients of heart allografts. Transplant Proc 1991; 23: 19-25
18. Steele DM, Hullett DA, Bechstein WO, et al. Effects of immunosuppressive therapy on the rat aortic allograft model. Transplant Proc 1993; 25: 754-5
19. Taylor DO, Ensley RD, Olsen SL, et al. Mycophenolate mofetil (RS-61443): preclinical, clinical, and three year experience in heart transplantation. J Heart Lung Transplant 1994; 13: 571-83
20. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and ester prodrug, mycophenolate mofetil. Immunol Rev 1993; 136: 5-28
21. Allison AC, Kowalski WJ, Muller CD, et al. Mechanisms of action of mycophenolic acid. Ann N Y Acad Sci 1993; 696: 63-87
22. Allison AC, Hovi T, Watts RWE, et al. The role of de novo purine synthesis in lymphocyte transformation. Ciba Found Symp 1977; 48: 221-7
23. Natsumeda V, Carr SF. Human type I and II IMP dehydrogenase as targets. Ann N Y Acad Sci 1993; 696: 88-93
24. Giblett ER, Anderson JA, Cohen F, et al. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972: II: 1067-9
25. Stryer L. Biosynthesis of nucleotides. In: Streyer L, editor. Biochemistry. 3rd ed. New York: W.H. Freeman, 1988: 602-26
26. Dayton J, Lindsten T, Thompsom CB, et al. Effects of human T lymphocyte activation on inosine monophosphate dehydrogenase expression. J Immunology 1994; 52: 984-91
27. Carr SF, Papp E, Wu JC, et al. Characterization of human type I and type II IMP dehydrogenase. J Biol Chem 1993; 268: 27286-90
28. Franklin TJ, Cook JM. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 1969; 113: 515-24
29. Sweeny MJ, Hoffman DH, Esterman MA. Metabolism and biochemistry of mycophenolic acid. Cancer Res 1972; 32: 1803-9
30. Lowe JK, Brox L, Henderson JF. Consequences of inhibition of guanine nucleoside synthesis by mycophenolic acid and virazole. Cancer Res 1977; 37: 736-43
31. Makara GM, Keseru GM, Katjar-Peredy M, et al. Nuclear magnetic resonance and molecular modeling study on mycophenolic acid: implications for binding to inosine monophosphate dehydrogenase. J Med Chem 1996; 39: 1236-42
32. Sintchak MD, Fleming MA, Futer O, et al. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 1996; 85: 921-30
33. Fleming MA, Chambers SP, Connelly PR, et al. Inhibition of IMPDH by mycophenolic acid: dissection of forward and reverse pathways using capillary electrophoresis. Biochem 1996; 35: 6990-7
34. Sollinger HW, Eugui EM, Allison AC. RS-61443: mechanism of action, experimental and early clinical results. Clin Transplant 1991; 5: 523-6
35. Freise CE, Hebert M, Osorio RW, et al. Maintenance immunosuppression with prednisone and RS-61443 alone following liver transplantation. Transplant Proc 1993; 25: 1758-9
36. Deierhoi MH, Sollinger HW, Diethelm AG, et al. One-year follow-up results of a phase 1 trial of mycophenolate mofetil (RS61443) in cadaveric renal transplantation. Transplant Proc 1993; 25: 693-4
37. Takahashi K, Ochiai T, Uchida K, et al. Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. Transplant Proc 1995; 27: 1421-4
38. Kirklin J, Bourge RC, Naftel DC, et al. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience. J Heart Lung Transplant 1994; 13: 444-50
39. Stegall MD, Everson GT, Wachs ME, et al. Prednisone withdrawal 14 days after adult liver transplantation- a randomized trial of tacrolimus and cyclosporine with mycophenolate mofetil [abstract]. Hepatology 1996; 24 (Pt 2): 174A
40. Holt C, Goss J, McDairmid S, et al. Efficacy and safety of low dose tacrolimus and mycophenolate mofetil in OLT recipients [abstract]. Hepatology 1996; 24 (Pt 2): 173A
41. Schiff MH, Goldblum R, Rees MMC. New DMARD mycophenolate mofetil (myco-m), efficacy treats refractory rheumatoid arthritis (RA) patients for one year [abstract]. Arthritis Rheum 1991; 34: S89
42. Laskow DA, Deierhoi MH, Orr CL, et al. The incidence of acute rejection following the treatment of refractory renal allograft rejection with mycophenolate mofetil (RS61443). Transplantation 1994; 57: 640-3
43. Islam MS, Francos GF, Burke JF. Mycophenolate mofetil is effective in the treatment of renal allograft dysfunction due to cyclosporine nephrotoxicity [abstract]. J Am Soc Nephrol 1996; 9: 1913
44. Eckoff DE, Ingram CO, Crocker RM, et al. Tacrolimus and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplant patients [abstract]. Hepatology 1996; 24 (Pt 2): 506A
45. Stratta RJ, First MR, Egid, et al. Simultaneous use of FK506 and mycophenolate mofetil in pancreas and kidney transplant recipients: a multicenter report [abstract]. XVI International Congress of the Transplantation Society; 1996: Barcelona Spain: 176
46. Stegall MD, Simon M, Wachs M, et al. Decreased rejection in simultaneous pancreas kidney transplantation with mycophenolate mofetil- a randomized trial of tacrolimus and cyclosporine [abstract]. ASTP 15th Annual Scientific Meeting; 1996: Dallas, TX: 192
47. Hebert M, Ascher N, Lake J, et al. Mycophenolate mofetil for prophylaxis against rejection following orthotopic liver transplantation [abstract]. XV International Congress of the Transplantation Society; 1994: Kyoto, Japan: 343
48. Hassanein T, Freeman J, Oculam CA, et al. Successful early steroid withdrawal using tacrolimus and mycophenolate protocol for liver transplantation [abstract]. Hepatology 1996; 24 (Pt 2: 521A
49. Fisher RA, Shiffman ML, Naar JD, et al. A prospective randomized trial of mycophenolate mofetil with Neoral or tacrolimus induction following orthotopic liver transplantation [abstract]. Hepatology 1996; 24 (Pt 2): 511A
50. John D, Morgan G, Diflo T, et al. Induction immunotherapy in liver transplantation with mycophenolate mofetil and steroids [abstract]. Hepatology 1996; 24 (Pt 2): 529A
51. Friese CE, Hebert MF, Osorio RW, et al. Maintenance immunosuppression with prednisone and rs-61443 alone after liver transplantation. Transplant Proc 1993; 25: 278-98
52. First MR, Schroeder TJ, Shah M, et al. A comparison of the safety and efficacy of two immunosuppressive regimens: mycophenolate mofetil, prednisone and cyclosporine and mycophenolate mofetil, prednisone and tacrolimus. Poster #227. Presented at 15th Annual meeting of the American Society of Transplant Physicians: 1996 May 26-30: Dallas (TX), USA
53. Gavlik A, Goldberg MS, Tsaroucha A, et al. Mycophenolate rescue therapy in liver transplant patients [abstract]. XVI International Congress of the Transplantation Society; 1997: Barcelona, Spain: 177
54. Dhawan A, Kaufman S, Pillen T, et al. Preliminary experience with mycophenolate mofetil as rescue therapy for liver allograft rejection in children [abstract]. Hepatology 1996; 24 (Pt 2): 304A
55. Kobashigawa JA, Renlund DG, Olsen SL. Initial results of rs-61443 for refractory cardiac rejection [abstract]. J Am Col Cardiol 1992; 19: 203A
56. Trotter J, Washington K, Kohli V, et al. Mycophenolate Mofetil is an effective treatment for steroid resistant acute cellular rejection [abstract]. Hepatology 1996; 24 (Pt 2): 173A
57. Morris-Stiff G, Jurewicz WA. Single center experience with mycophenolate mofetil for refractory rejection. Transplant Int 1998; 11: 204-7
58. Woodle ES, Jordan ML, Facklam D, et al. Meta-analysis of mycophenolate mofetil refractory rejection trials in renal transplantation. Transplant Proc 1998; 30: 1297-8